Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2870 vs platinum doublet chemotherapy in EGFR-mutated advanced nonsquamous NSCLC after EGFR TKI
jRCT2071240041Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of sacituzumab tirumotecan in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck & Co. Primary endpoints: Progression-Free Survival and Overall Survival. Started Aug 2024; status: active, not recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2071240041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240041.